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The	striatum receives	glutamate	and dopamine	from	Substantia	nigra	pars	compacta	and	almost	all	cortical	areas2.		Receiving	these	inputs	early	in	development	is	crucial	for	proper	development	of	a	MSN,	as	shown	below.	
glutamate
dopamine
95%	of	the	neurons	found	in	the	striatum (caudate	+	putamen)	are	Medium	Spiny	Neurons2.	
Medium	Spiny	Neuron	(MSN)
AbstractThe	Lanier	Lab	has	previously	shown	that	dopamine	(DA)	increases	dendritic	branching	and	spine	density	in	Medium	Spiny	Neurons1.	The	goal	of	these	experiments	is	to	find	the	mechanism	by	which	dopamine	impacts	MSN	development.
High	dendritic	spine	density
Background
Extensive	branching	dendrites
MSN	differentiation	is	required	for	normal	brain	function.	Deviations	from	this	characteristic	morphology	is	associated	with	the	following	neurodevelopmental	disorders:
• Tourette’s
• OCD
• Autism3
Negative	control	 DA	only PLC	antagonist DREADDs	and	CNO
Methods41. Dissect	embryonic	mouse	brain	(diagram)2. Allow	MSNs	to	grow	19	div3. Fix	4. Prepare	coverslips	by	incubating	overnight	with	immunofluroscentprimary	antibody	DARPP-32,	a	protein	expressed	in	MSNs	5. Visualize	with	epifluorescent	microscope	at	20x	objective6. Quantify	dendritic	arborization	using	Sholl	Analysis
Alternative	MechanismCanonical	Mechanism	
Hypothesis:	Dopamine	increases	dendritic	branching	one	of	these	mechanisms:
To	test	whether	the	Gq protein	is	being	activated	in	this	mechanismDesigner	Receptor	Exclusively	Activated	by	Designer	Drugs	(DREADDs)—
• A	G	protein	coupled	receptor	that	uses	the	Gq signaling	pathway
• Expressed	in	MSNs	by	plasmid	electroporation
• Administration	of	drug	Clozapine	N-oxide	activates	receptor	
DREADDs!
ResultsCNO	results	in	as	much	branching	as	dopamine.	This	suggests	that	Gq is	being	activated	in	dopamine’s	mechanism	to	increase	dendritic	branching.		
Cut	out	 part	of	cortex
Isolate	striatumPlace	cortex	and	striatum	on	separate	petri	dishes
Plate	cells	at	200	cells/mm2 at	a	ratio	of	3	parts	cortex	to	2	parts	striatum	
Digest	with	0.25%	trypsin-EDTADissociate	
Future	DirectionsThe	goal	is	to	find	the	exact	mechanism	by	which	dopamine	increases	dendritic	branching	in	the	growing	MSN.	This	will	be	done	by:1. Confirming	the	role	of	PLC in	the	mechanism	using	D1/D2	receptor	agonist	SKF83959	which	is	known	to	selectively	stimulate	PLC	2. Examining	the	effect	of	inhibiting	Protein	Kinase	C	(PKC)	with	drug	Riluzole3. Inhibiting	Calmodulin-dependent	protein	kinase	II	(CaMKII)	with	KN-93
Expected	results1. If	PLC	is	involved,	SKF83959	will	replicate	dopamine’s	effect	of	dendritic	branching2. If	PKC	is	involved,	inhibiting	PKC	will	result	in	significantly	less	dendritic	branching	even	with	DA	administration3. If	CaMKII is	involved,	the	inhibitor	will	decrease	dopamine’s	branching	effect	
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Concentric	circles	radiating	from	soma	are	used	to	evaluate	the	complexity	of	the	dendritic	arbor
Results
ConclusionThe	receptors	activated	by	DA	are	structurally	different	than	those	bound	by	the	agonists.		Literature	suggests	the	existence	of	a	structurally	distinct	D1/D2	heterodimer	that	activates	Gq5
Phospholipase	C	(PLC)	inhibitor	antagonist	U73122	significantly	reduces	the	effects	of	DA.	
ConclusionActivator	enzyme	PLC	is	used	in	dopamine’s	pathway	to	increase	dendritic	branching
A	D1	agonist	SKF82958	and	a	D2	agonist	Quinprole neither	in	isolation	nor	together	could	mimic	the	effects	of	dopamine	(DA).	
2	way	ANOVA*	=	0.05**	=	0.001***	=	0.0005****	=0.0001
